@article{Postma:2019:10.1016/S2213-2600(19)30049-9,
author = {Postma, DS and Brightling, C and Baldi, S and Van, den Berge M and Fabbri, LM and Gagnatelli, A and Papi, A and Van, der Molen T and Rabe, KF and Siddiqui, S and Singh, D and Nicolini, G and Kraft, M and ATLANTIS, study group},
doi = {10.1016/S2213-2600(19)30049-9},
journal = {Lancet Respir Med},
pages = {402--416},
title = {Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.},
url = {http://dx.doi.org/10.1016/S2213-2600(19)30049-9},
volume = {7},
year = {2019}
}

Download

TY  - JOUR
AB  - BACKGROUND: Small airways dysfunction (SAD) is well recognised in asthma, yet its role in the severity and control of asthma is unclear. This study aimed to assess which combination of biomarkers, physiological tests, and imaging markers best measure the presence and extent of SAD in patients with asthma. METHODS: In this baseline assessment of a multinational prospective cohort study (the Assessment of Small Airways Involvement in Asthma [ATLANTIS] study), we recruited participants with and without asthma (defined as Global Initiative for Asthma severity stages 1-5) from general practices, the databases of chest physicians, and advertisements at 29 centres across nine countries (Brazil, China, Germany, Italy, Spain, the Netherlands, the UK, the USA, and Canada). All participants were aged 18-65 years, and participants with asthma had received a clinical diagnosis of asthma more than 6 months ago that had been confirmed by a chest physician. This diagnosis required support by objective evidence at baseline or during the past 5 years, which could be: positive airway hyperresponsiveness to methacholine, positive reversibility (a change in FEV1 ≥12% and ≥200 mL within 30 min) after treatment with 400 μg of salbutamol in a metered-dose inhaler with or without a spacer, variability in peak expiratory flow of more than 20% (measured over 7 days), or documented reversibility after a cycle (eg, 4 weeks) of maintenance anti-asthma treatment. The inclusion criteria also required that patients had stable asthma on any previous regular asthma treatment (including so-called rescue β2-agonists alone) at a stable dose for more than 8 weeks before baseline and had smoked for a maximum of 10 pack-years in their lifetime. Control group participants were recruited by advertisements; these participants were aged 18-65 years, had no respiratory symptoms compatible with asthma or chronic obstructive pulmonary disease, normal spirometry, and normal airways responsiveness, an
AU  - Postma,DS
AU  - Brightling,C
AU  - Baldi,S
AU  - Van,den Berge M
AU  - Fabbri,LM
AU  - Gagnatelli,A
AU  - Papi,A
AU  - Van,der Molen T
AU  - Rabe,KF
AU  - Siddiqui,S
AU  - Singh,D
AU  - Nicolini,G
AU  - Kraft,M
AU  - ATLANTIS,study group
DO  - 10.1016/S2213-2600(19)30049-9
EP  - 416
PY  - 2019///
SP  - 402
TI  - Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.
T2  - Lancet Respir Med
UR  - http://dx.doi.org/10.1016/S2213-2600(19)30049-9
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30876830
VL  - 7
ER  - 

Download